CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-12-19): Vertex strengthens warning on telaprevir for hep C

Clinical

Vertex strengthens warning on telaprevir for hep C

Last Updated: 2012-12-19 13:00:20 -0400 (Reuters Health)

(Reuters) - Vertex Pharmaceuticals Inc warned on Wednesday its hepatitis C drug telaprevir (Incivek), which is used in conjunction with two other drugs, can cause serious, potentially fatal skin reactions.

Skin rashes were already a known side effect of Incivek, but an analysis of data since the drug was approved in the United States in 2011 has revealed a number of cases in which the reaction was more severe than those seen in clinical trials of the drug. Some were fatal.

The findings have led Cambridge, Massachusetts-based Vertex to place an enhanced warning, surrounded by a black box, on the drug's prescribing label.

Incivek, Vertex's flagship product, is approved to treat hepatitis C in combination with interferon and ribavirin.

The company said the fatal cases of skin reactions occurred in patients who continued to receive Incivek combination treatment after a serious skin reaction was identified.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.